AstraZeneca Announced Earlier, Enhertu Approved In The EU as First HER2-Directed Therapy For Patients With HER2-Mutant Advanced NSCLC
Portfolio Pulse from Charles Gross
AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the European Union for the treatment of adult patients with advanced non-small cell lung cancer. This approval makes Enhertu the first HER2-directed therapy for patients with HER2-mutant advanced NSCLC in the EU.
October 23, 2023 | 9:33 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AstraZeneca's Enhertu has received approval in the EU, potentially increasing the company's market share in the region.
The approval of Enhertu in the EU is a significant milestone for AstraZeneca. This could potentially increase the company's market share in the region, as it is the first HER2-directed therapy for patients with HER2-mutant advanced NSCLC. This could lead to increased revenues for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100